Efficacy of a BCNU-based high dose conditioning regimen (CBV1) followed by autologous hematopoietic stem cell transplantation (HSCT) in relapsed or refractory Hodgkin's disease (HD).

被引：0
|
作者：
Qazilbash, MH [1 ]
Lynch, JP [1 ]
Beall, CL [1 ]
Auber, M [1 ]
Weisenborn, R [1 ]
Bunner, P [1 ]
Hobbs, G [1 ]
Ericson, SG [1 ]
机构：
[1] W Virginia Univ, BMT Sect, Morgantown, WV 26506 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5369
引用
收藏
页码：374B / 374B
页数：1
相关论文
共 50 条
  • [41] Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma
    Damlaj, Moussab
    Alaskar, Ahmed
    Alahmari, Bader
    Ghazi, Samer
    Hejazi, Ayman
    Alzahrani, Mohsen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S233 - S233
  • [42] Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma
    Hazar, Volkan
    Kesik, Vural
    Aksoylar, Serap
    Karakukcu, Musa
    Ozturk, Gulyuz
    Kupesiz, Alphan
    Atas, Erman
    Oniz, Haldun
    Kansoy, Savas
    Unal, Ekrem
    Tanyeli, Atila
    Erbey, Fatih
    Elli, Murat
    Tacyildiz, Nurdan
    Karasu, Gulsun Tezcan
    Kocak, Ulker
    Anak, Sema
    Bengoa, Sebnem Yilmaz
    Sezgin, Gulay
    Atay, Didem
    Unal, Emel
    Uygun, Vedat
    Kurucu, Nilgun
    Kaya, Zuhre
    Yesilipek, Akif
    PEDIATRIC TRANSPLANTATION, 2015, 19 (07) : 745 - 752
  • [43] Autologous stem cell transplantation (ASCT) in 100 patients with Hodgkin's disease (HD) in first relapse (1st rel): Impact of the conditioning regimen [Fractionated total body irradiation (FTBI)-based versus BCNU-based] on the patterns of treatment failure.
    Fung, HC
    Nademanee, A
    Molina, A
    Ruel, C
    Ivers, B
    Smith, D
    Krishnan, A
    Popplewell, L
    Vora, N
    Synder, D
    O'Donnell, M
    Parker, P
    Stein, A
    Somlo, G
    Falk, P
    Kogut, N
    Spielberger, R
    Rodriguez, R
    Rosenthal, J
    Schriber, J
    Bhatia, R
    Bhatia, S
    Alvarnas, J
    Sweetman, R
    Cohen, S
    Sahebi, F
    Forman, SJ
    BLOOD, 2001, 98 (11) : 678A - 678A
  • [44] Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease
    Reece, DE
    Nevill, TJ
    Sayegh, A
    Spinelli, JJ
    Brockington, DA
    Barnett, MJ
    Klingemann, HG
    Connors, JM
    Nantel, SH
    Shepherd, JD
    Sutherland, HJ
    Voss, NJS
    Fairey, RN
    O'Reilly, SE
    Phillips, GL
    BONE MARROW TRANSPLANTATION, 1999, 23 (11) : 1131 - 1138
  • [45] Allogeneic peripheral blood stem cell transplantation after a reduced conditioning regimen in refractory or relapsed Hodgkin's disease.
    Sureda, A
    Seyfarth, B
    Canals, C
    Fernández-Avilés, F
    Caballero, MD
    Hernández-Navarro, F
    Arranz, R
    Díez, JL
    Sanz, G
    Solano, C
    Martino, R
    Rovira, M
    Schmitz, N
    BLOOD, 2001, 98 (11) : 412A - 412A
  • [46] Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease
    DE Reece
    TJ Nevill
    A Sayegh
    JJ Spinelli
    DA Brockington
    MJ Barnett
    H-G Klingemann
    JM Connors
    SH Nantel
    JD Shepherd
    HJ Sutherland
    NJS Voss
    RN Fairey
    SE O’Reilly
    GL Phillips
    Bone Marrow Transplantation, 1999, 23 : 1131 - 1138
  • [47] High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) for lymphocyte predominant Hodgkin's disease.
    Bierman, Philip
    Naushad, Hina
    Loberiza, Fausto
    Gregory Bociek, R.
    Vose, Julie M.
    Armitage, James Olen
    Aoun, Patricia
    BLOOD, 2006, 108 (11) : 872A - 872A
  • [48] Efficacy of PD1-blockade immediately followed by autologous stem cell transplantation in relapsed/refractory hodgkin's lymphoma, but investigations needed to elucidate the impact on autologous transplantation
    Ibrahim, A.
    Khalil, A.
    Abyad, A.
    Harmouche, A.
    Ibrahim, J.
    Al Zahran, K.
    Mogharbel, A.
    Jalloul, R.
    Youssef, A.
    Jisr, T.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 305 - 306
  • [49] Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation
    Fernandez de Larrea, C.
    Martinez, C.
    Gaya, A.
    Lopez-Guillermo, A.
    Rovira, M.
    Fernandez-Aviles, F.
    Lozano, M.
    Bosch, F.
    Esteve, J.
    Nomdedeu, B.
    Montserrat, E.
    Carreras, E.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1211 - 1216
  • [50] High-dose chemotherapy and autologous stem cell transplantation for Korean patients with relapsed or refractory Hodgkin's lymphoma
    Park, K.
    Yoon, D.
    Kim, S.
    Huh, J.
    Park, C.
    Lee, S.
    Park, S.
    Ahn, Y.
    Jo, J.
    Suh, C.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S445 - S445
12345